CellaVision AB (CLVSF) Price & Analysis

CellaVision AB released its earnings results on Nov 06, 2025. The company reported $0.142 earnings per share for the quarter, beating the consensus estimate of $0.116 by $0.026.

Is CellaVision AB overvalued?

According to Wall Street analysts CellaVision AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CellaVision AB pay dividends?

CellaVision AB pays a Annually dividend of $0.263 which represents an annual dividend yield of 1.37%. See more information on CellaVision AB dividends here

What is CellaVision AB’s EPS estimate?

CellaVision AB’s EPS estimate is 0.15.

How many shares outstanding does CellaVision AB have?

CellaVision AB has 23,851,547 shares outstanding.

What happened to CellaVision AB’s price movement after its last earnings report?

CellaVision AB reported an EPS of $0.142 in its last earnings report, beating expectations of $0.116. Following the earnings report the stock price went down -7.996%.

Which hedge fund is a major shareholder of CellaVision AB?

Currently, no hedge funds are holding shares in CLVSF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CellaVision AB

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

CellaVision AB (CLVSF) Earnings & Revenues

Historic Earnings Reports

CLVSF Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with several strategic advancements and organic growth offset by regional performance issues and currency headwinds. The company's strategic initiatives and innovation efforts show potential for future growth, but current challenges in certain markets and financial metrics present areas of concern.View all CLVSF earnings summaries